Clinical application of palbociclib as a treatment of cancer

Congming Wu

doi:10.1117/12.2692211

7 September 2023 Clinical application of palbociclib as a treatment of cancer

Congming Wu

Proceedings Volume 12789, International Conference on Modern Medicine and Global Health (ICMMGH 2023); 127892Y (2023) https://doi.org/10.1117/12.2692211
Event: International Conference on Modern Medicine and Global Health (ICMMGH 2023), 2023, Oxford, United Kingdom

Abstract

One of the most frequent malignant tumors in women is breast cancer, and its prevalence is rising every year. In Europe and in United States, 25 to 30 percent of all cancers in women are breast cancers. Every year, 1.3 million women are given a breast cancer diagnosis worldwide, and 400,000 of them will die from the condition. Currently, breast cancer has become the biggest threat to women's health. The causes of breast cancer are multifaceted and extremely complex. Genes like breast cancer type (BRCA) 1, BRCA2, and tumor protein p53 (P53) are linked to familial breast cancer. Breast cancer risk factors include high estrogen levels post menopause, estrogen replacement medication, early menarche, late menopause, short menstrual cycles, and other sex hormone related variables. Palbociclib, a cyclin-dependent kinases (CDKs) inhibitor, has been applied as a treatment for advanced breast cancer. It can also be combined with other chemotherapies or radiotherapies to improve its effectiveness. Despite its side effects, it is currently the better targeted drug for the treatment of breast cancer.

Citation Download Citation

Congming Wu "Clinical application of palbociclib as a treatment of cancer", Proc. SPIE 12789, International Conference on Modern Medicine and Global Health (ICMMGH 2023), 127892Y (7 September 2023); https://doi.org/10.1117/12.2692211

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available